seed
Stage
1
Investors
About
AxCell Labs develops regenerative soft-tissue implants made from a purified bacterial cellulose biomaterial, including a dermal injectable, aimed at reconstructing rather than simply filling soft tissues. The company has completed preclinical biocompatibility studies, filed a PCT patent, raised seed funding, and is preparing for regulatory preclinical studies toward clinical trials.
Explore AxCell Labs's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.